Previous 10 | Next 10 |
FLORHAM PARK, N.J., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a partnership to advance the...
2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...
2024-01-09 12:40:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cutera Inc (NASDAQ: CUTR), Sentage Holdings (NASDAQ: SNTG), NexImmune Inc (NASDAQ: NEXI), Adicet Bio In...
2024-01-09 01:05:44 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Cellectar Biosciences, Inc. (NASDAQ: CLRB), Aclarion, Inc. (NASDAQ: ACON), Ardelyx (NASDAQ: ARDX), Sidus Space Inc. (NASDAQ: SIDU), NexImmune Inc. (NASDA...
2024-01-08 12:34:45 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aclarion Inc (NASDAQ: ACON), Spectaire Holdings Inc (NASDAQ: SPEC), Cellectar Biosciences Inc (NASDAQ: ...
2024-01-08 10:13:03 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Vincerx Pharma Inc (NASDAQ: VINC), Canoo Inc (NASDAQ: GOEV), Aclarion Inc (NASDAQ: ACON), Spectaire Holdings I...
2024-01-08 07:15:09 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...
2024-01-08 06:56:58 ET DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported, this morning, data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treat...
Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate; 61% Major Response Rate ( 95% CI, 44.5%, 75.8%) ; 100% Disease Control Rate exceeding protocol statistical hurdle of 20% ...
Management to host conference call on Monday, January 8, 2024, at 8:00 am ET Company also to present at the Biotech Showcase FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...